This story originally ran on March 4.

A new company, Ubiquigent, has been formed to develop reagents and kits to help "advance understanding of the biology of the ubiquitin proteasome pathway."

Based in Dundee, Scotland, Ubiquigent is operating as a subsidiary of stem cell firm Stemgent, which plans to invest $4.5 million into Ubiquigent over the next three years.

Stemgent is based in Boston and San Diego. Ubiquigent is Stemgent's first overseas company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.